BACKGROUND: CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics. METHODS: We investigated the effect of CYP3A5 6986A>G polymorphism (CYP3A5*1/*3 alleles) on the pharmacokinetics of everolimus in 28 renal transplant patients and on its in vitro hepatic metabolism using a bank of genotyped human liver microsomes (n=49). We further evaluated in vitro the contribution of CYP3A4, CYP3A5, and CYP2C8 to everolimus hepatic metabolism using recombinant enzymes. RESULTS: We found no association between CYP3A5 polymorphism and everolimus pharmacokinetics in renal transplant patients. On the other hand, no effect of CYP3A5 polymorphism was observed on the intrinsic clearance of everolimus by human liver microsomes, whereas that of tacrolimus (positive control) was 1.5-fold higher in microsomes carrying the CYP3A5*1 allele than in noncarriers. In vitro data showed that CYP3A4 is a better catalyst of everolimus metabolism than CYP3A5, whereas the opposite was observed for tacrolimus. CONCLUSIONS: This study provides direct and indirect evidence that CYP3A5 genotyping cannot help improve everolimus therapy.
BACKGROUND:CYP3A5 genotyping might be useful to guide tacrolimus and sirolimus dosing. The aim of this study was to assess the influence of CYP3A5 polymorphism on everolimus metabolism and pharmacokinetics. METHODS: We investigated the effect of CYP3A5 6986A>G polymorphism (CYP3A5*1/*3 alleles) on the pharmacokinetics of everolimus in 28 renal transplant patients and on its in vitro hepatic metabolism using a bank of genotyped human liver microsomes (n=49). We further evaluated in vitro the contribution of CYP3A4, CYP3A5, and CYP2C8 to everolimus hepatic metabolism using recombinant enzymes. RESULTS: We found no association between CYP3A5 polymorphism and everolimus pharmacokinetics in renal transplant patients. On the other hand, no effect of CYP3A5 polymorphism was observed on the intrinsic clearance of everolimus by human liver microsomes, whereas that of tacrolimus (positive control) was 1.5-fold higher in microsomes carrying the CYP3A5*1 allele than in noncarriers. In vitro data showed that CYP3A4 is a better catalyst of everolimus metabolism than CYP3A5, whereas the opposite was observed for tacrolimus. CONCLUSIONS: This study provides direct and indirect evidence that CYP3A5 genotyping cannot help improve everolimus therapy.
Authors: P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz Journal: Nat Genet Date: 2001-04 Impact factor: 38.330
Authors: Iain A M Macphee; Salim Fredericks; Maha Mohamed; Michelle Moreton; Nicholas D Carter; Atholl Johnston; Lawrence Goldberg; David W Holt Journal: Transplantation Date: 2005-02-27 Impact factor: 4.939
Authors: Michel Mourad; Georges Mourad; Pierre Wallemacq; Valérie Garrigue; Christophe Van Bellingen; Valérie Van Kerckhove; Martine De Meyer; Jacques Malaise; Djamila Chaib Eddour; Dominique Lison; Jean Paul Squifflet; Vincent Haufroid Journal: Transplantation Date: 2005-10-15 Impact factor: 4.939
Authors: Dany Anglicheau; Delphine Le Corre; Sophie Lechaton; Pierre Laurent-Puig; Henri Kreis; Philippe Beaune; Christophe Legendre; Eric Thervet Journal: Am J Transplant Date: 2005-03 Impact factor: 8.086
Authors: Dirk Jan A R Moes; Rogier R Press; Jan den Hartigh; Tahar van der Straaten; Johan W de Fijter; Henk-Jan Guchelaar Journal: Clin Pharmacokinet Date: 2012-07-01 Impact factor: 6.447
Authors: Ida Robertsen; Jean Debord; Anders Åsberg; Pierre Marquet; Jean-Baptiste Woillard Journal: Clin Pharmacokinet Date: 2018-11 Impact factor: 6.447